Skip to main content
OpenTrials

Clinical trial condition

Urinary Bladder Diseases

Explore clinical trials studying Urinary Bladder Diseases. Study availability and eligibility vary by location and protocol.

2,285 public trials 413 recruiting studies
Refine in advanced search Browse all conditions

Urinary Bladder Diseases trial results

Active, Not Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Active, Not Recruiting

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

NCT03047213

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +18 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

NCT02496208

Conditions
Adenocarcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, +54 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082

Conditions
Bladder Flat Urothelial Carcinoma In Situ, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 391 locations
View Trial Details
Active, Not Recruiting

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +8 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Goodyear, Arizona, United States
  • Research Site Fort Myers, Florida, United States
  • Research Site St. Petersburg, Florida, United States
View all 44 locations
View Trial Details
Active, Not Recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +16 more
Locations
  • Arizona Urology Specialists Tucson, Arizona, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
  • Genesis Research San Diego, California, United States
  • Wichita Urology Group Wichita, Kansas, United States
View all 65 locations
View Trial Details
Active, Not Recruiting

Continence Care Registry

NCT04924569

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infections, +17 more
Locations
  • Hollister Incorporated Libertyville, Illinois, United States
View Trial Details
Active, Not Recruiting

Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

NCT03757949

Conditions
Bladder Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States
View all 46 locations
View Trial Details
Active, Not Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +8 more
Locations
  • Washington Cancer Institute at MedStar Washington Hospital Center ( Site 0041) Washington D.C., District of Columbia, United States
  • Bay Pines VA Medical Center ( Site 0055) Bay Pines, Florida, United States
  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0004) Orlando, Florida, United States
  • Norton Cancer Institute ( Site 0044) Louisville, Kentucky, United States
View all 134 locations
View Trial Details

Related conditions